Gilead Sciences Canada Recognized for Developing Harvoni as Hepatitis C Therapy
Hepatitis C, News
Gilead Sciences Canada has been awarded this year’s Prix Galien Canada–Innovative Product Award for the development of Harvoni (ledipasvir/sofosbuvir), a once-daily combination pill for the treatment of chronic genotype 1 hepatitis ... Read more